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in 9 of l0  Families 
By Stefan Mustafa, Ingrid Pabinger, and Christine Mannhalter 
We identified potentially causative mutations in  the active 
protein S gene (PROS 1) by direct sequencing  of  PROS 1- 
specific polymerase chain reaction (PCR) products of all 15 
exons, including exon-intron boundaries in 10 families with 
hereditary protein S deficiency type 1.  Seven different muta- 
tions were found in 9 of  10 families,  including one frame 
shift mutation, a previously published splice site mutation 
(both occurring in two unrelated families), four  missense 
mutations, and a stop codon at  the beginning of  exon 12. 
In family studies,  cosegregation of  the  mutation  with  the 
disease  could  be demonstrated for five mutations; for two 
P 
ROTEIN C and its cofactor, protein S, play  an important 
role in the anticoagulant system."'  Protein C, a vitamin 
K-dependent glycoprotein,  is  activated  by  the  thrombin- 
thrombomodulin complex  to  activated protein  C  (APC), 
which, in the presence of its cofactor, protein S, selectively 
inhibits the procoagulant cofactors factor VIIIa  and  factor 
Va,  thereby  downregulating the coagulation cascade.'  Pro- 
tein S, also a vitamin K-dependent glycoprotein, is synthe- 
sized in the liver:  endothelial cells,s and a number of other 
tissues. Its mRNA is also found in platelets.6  Protein S circu- 
lates in plasma in part as complex (60%)  with C4b-binding 
protein (C4BP) and in part as unbound, free form (40%).7 
It  has been shown that only free protein  S is functionally 
active in  the  protein C anticoagulant pathway.' 
The concentration of protein S in plasma  is  usually deter- 
mined  by  measurements of  antigen (free or  total  protein 
S) and/or activity. Most cases of  protein S-deficiency are 
classified as type I deficiency  with reduced levels of  antigen 
and  activity.'  Few  reports describe cases of  type I1 (normal 
total and free antigen, reduced activity)'0,'' and type 111 (nor- 
mal total antigen, reduced free antigen and activity)I2  defects 
(type attribution according to SSC Subcommittee Meeting, 
Munich, Germany, 1993). 
Homozygous protein C or  protein  S deficiency  can  lead 
to  life-threatening thrombotic  complications  shortly  after 
birth.I3 Heterozygous individuals have a significant risk  to 
develop venous thrombosis, but  at  a later age  and  usually 
with  milder  Using  the currently available 
laboratory test systems, it  is  sometimes difficult to identify 
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missense mutations, this was  not  possible due to  limited 
family data. All seven mutations were  the  only abnormalities 
identified in  the respective index patients and were absent 
in 44 to 62 normal individuals. Therefore, they most likely 
represent the causal gene defects.  For  five mutations, analy- 
sis  of  ectopic  RNA could be performed. Mutant transcripts 
were present in  the  case  of the frame shift and three of the 
missense  mutations, while  no  mutant RNA could be de- 
tected in  the case  of  the stop codon. 
0  1995 by The  American  Society of Hematology. 
heterozygous protein S-deficient individuals. All test systems 
show a considerable overlap between  protein  S plasma levels 
found in  normal individuals and in deficient heterozygotes. 
Especially in the case of  oral anticoagulation, the diagnostic 
uncertainty  with conventional test systems is  very high. Only 
a genetic approach that identifies the causative mutations in 
protein S-deficient individuals can bypass these diagnostic 
pitfalls. 
Protein S is encoded by the active PROS  1 gene on chro- 
mosome 3, and  an  inactive pseudogene, PROS 2, also exists 
on  chromosome 3.lh.I7 PROS 2, which  is  not  transcribed, 
shows a homology of  97%  with  PROS  1, but differs by the 
absence of exon 1 and  the  presence of stop codons within the 
gene."-'"  It  can  be expected that mutations causing protein S 
defects will  be  located within  the  PROS  1 gene. To date, 
two major deletions2'.''  and  21 point mutations".23-2h  in  the 
PROS 1 gene have been  reported  as putatively causal muta- 
tions in protein  S deficiency. Analysis of  PROS  1  mRNA 
was  shown  to  be  unsatisfactory to search for mutations in 
protein S-deficient families, as gene defects interfering with 
mRNA  synthesis and/or processing remained  undetected.' 
In contrast, the screening of  the 15 individual exons and  the 
exonhntron boundaries of  the  PROS  1  gene allows identifi- 
cation of  all genomic mutations in the coding region  and the 
splice junction sites. 
Using this approach, we  identified  mutations in  9 of  IO 
individuals with  protein  S deficiency. The nine individuals 
shared seven different mutations; two mutations occurred in 
two subjects each. Interestingly, one of  these mutations (a 
splice site mutation  at  position +5  of  the donor splice site 
of  intron 10) has previously been reported in two unrelated, 
protein S-deficient patients of  Dutch origin.27  Whether this 
splice site mutation represents a mutational  hot  spot remains 
to  be  determined. 
PATIENTS  AND  METHODS 
Patients.  The protein S-deficient patients selected for the study 
were identified during the investigation of individuals with a history 
of objectively documented thrombosis and/or pulmonary embolism. 
Individuals who  had  developed thrombosis early in  life (before 45 
years of age) or who  had  a positive family history (around 30% of 
all investigated patients) were screened for protein S deficiency by 
determination of free protein S  antigen (Table I).  In patients found 
to  he  protein  S-deficient, as well as in their relatives, free and total 
protein S values were measured. Between 1985  and 1994, 19 families 
with protein S deficiency type I  were identified. From  the  19  index 
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Table 1.  Clinical  Characteristics  and  Protein S Values of  Protein  S-Deficient  Individuals  and  Their  Relatives 
Age at Last 
Patient  Free Protein  Total Protein  Heterozygous  Age at First  Recurrent  Examination 
Code No.  S  (%)  S  (%l  OAC  Mutation  Thrombosist  Thrombosis (yr)  Thrombosis  (yr) 
1-111  15  40  +  +  22  +  68 
1-11/2  14  37  +  +  21  +  40 
- 
1-11/1  86 
-  86  -  -  -  -  46 
- 
1  -l  113  130 
-  118  -  -  -  43  45 
1-11/4*  7  26  +  +  +  29  +  39 
1-111/1  90  -  17 
1-111/2  15  40  -  +  15 
1-11113  76  88  12 
2-111  2  29  +  +  +  21  +  53 
2-112  7  48  -  +  +  19  +  44 
2-1/3*  3  31  +  +  +  37 
-  51 
2-1111  108  -  90  31 
2-1112  10  42  -  +  20 
2-1113  74  80  -  26 
3-111 *  4  81  +  +  20  +  44 
-  24 
-  80  -  -  - 
-  -  - 
-  -  -  -  - 
-  -  -  - 
-  -  - 
-  -  -  - 
- 
3-1111  7  54  -  +  +  27 
4-111 *  2  8  +  +  +  32  +  54 
4-1111  48  107  -  -  -  -  -  23 
5-111 *  1  18  +  ?  +  18  +  64 
6-111 *  2  30  +  +  +  25  +  43 
6-112  84  90  -  - 
6-11/1  16  64  -  +  - 
6-1112  18  56  -  +  - 
-  -  -  40 
11 
14 
7-111 *  30  86  -  +  +  18  +  55 
7-1111  38  59  -  +  -  22 
8-111  16  59  -  +  +  21  +  75 
-  - 
-  - 
-  - 
8-1111  11  57  -  +  +  46  -  54 
8-1112  100  92  -  -  57 
8-1113  9  47  -  +  +  20  +  52 
84lI/l*  2  26  +  +  +  16  +  23 
-  -  - 
8-111/2  20  61  -  +  +  19  -  24 
9-111 *  2  26  +  +  +  21  +  40 
9-112  14  84  -  +  +  26  -  34 
10"  4  29  +  +  +  23  +  69 
10-1/2*  4  23  +  +  +  57  +  67 
10-11/1  100  96  -  -  -  -  -  46 
1  0-1 1/2  122  116  -  -  -  -  -  44 
1  0-1 113  23  49  -  +  -  -  -  37 
Abbreviation: ?,  mutation not  identified. 
* Index patient. 
t Thromboses observed in patients were pulmonary embolism and/or deep venous thrombosis, one cerebral venous thrombosis (14/4), one 
mesenteric vein thrombosis (9-l11), and one cava vein thrombosis (5.111). 
patients, a panel  of  10 probands was  selected for  the  molecular 
biologic investigations. All index patients had a positive family his- 
tory for thromboembolism. Except patient 942,  who is an Argentin- 
ean of European origin, and patient 5-I/1,  who is German, all index 
patients are Austrians. 
Protein S determination and diagnostic criteria.  Free and total 
protein S antigen were measured by  a commercial enzyme-linked 
immunosorbent  assay  (Boehringer-Mannheim,  Mannheim,  Ger- 
many). For determination of free protein S, bound protein S was 
precipitated with polyethyleneglycol (PEG 8000; 3.75%) according 
to the method of  Comp et al,'* and free protein S was determined 
in the supernatant. The amount of free protein S in PEG-precipitated 
pooled normal plasma was  defined  as 100%. 
The lower limit of  the  normal range for free protein S was 64% 
in patients without oral anticoagulant (OAC) treatment and  19% for 
patients on OAC. For total protein S, the lower limit of the normal 
range was 65% in patients without and 35%  in patients with  OAC 
treatment. 
The diagnosis of  hereditary protein S deficiency type I was consid- 
ered as established when decreased free and total protein S values 
were repeatedly found in a proband  and  when  protein S deficiency 
was detected in at least one further relative, irrespective of the throm- 
botic history in that individual. Using the above-mentioned cut-off 
limits, in three families (families 3, 7, and  9).  individuals with de- 
creased free but normal total protein S  values (patients 3-U1, 7-I/1, 
and  942) were found in  addition to  the typical type  I-deficient 
patients. Families in which all deficient family members had  type 
111  deficiency were not included in our study. 
Genomic  DNA  analyses.  Genomic  DNA  was  extracted from 
EDTA or citrated blood samples (5 mL) according to standard proce- 
dures. For the identification of mutations, we concentrated on the 
analysis of the transcribed regions of the PROS 1 gene. Polymerase 
For personal use only. on November 2, 2014.  by guest    www.bloodjournal.org From 7 
8 
9 
10 
11 
12 
13 
14 
15A 
3446  MUSTAFA, PABINGER, AND MANNHALTER 
Table 2.  Nuclsotide  Sequences  of the Primers  Used  for PCR Amplification  and  Sequencing 
Exon  Primer  Primer  Sequence (5'-3')  Location* 
1  PS 0/4t§  5"GAA  GAA GGA TGT CTC  AGC  AGT-3' 
2  PS  211 t§  5"CAT  ATA AAC TGA TTG TTT CC-? 
3  PS  4/4t  5  5"m  AGG TTT GCT AAG ATA TG-3' 
PS  4/5t§ 
PS  411  t  §  5"ACC  TCT  TGG  GAC  AGT TCC TA-3' 
PS  5/2t 
PS  611 t  §  5"W  TAT TTT TCC ATG  ACA  TGA  GA-3' 
PS  6/25 
PS  1/4t§ 
-181  to -161 
5"TCT  AGG  AGC  TGC  AGC  TCT  AG-3'  +81 to +l00 
PS  311 t  5 
-25  to -6 
5"TAG  TTG  TAT GTC TAG  ATG  TG-3'  +30 to +49 
-41  to -22 
+96 to +l15 
-83  to -64 
+35 to +57 
-56 to -34 
-82  to -68 
5"TCC  CAA GGA TAA TGA AAT TA-3' 
4 
5"GTA  CTT  TAC  CTA  CAG AGT TTT TG-3' 
5 and 6 
5"CCA  GCT  CAT  CAG  GAT-3' 
PS 7/2t  5"AAC  TGG  GAT TAT TCT  CAC  AT-3' 
PS 8/6t  § 
PS  812  t  §  5"GAT  CAG  TAA TGA TAC  CAC  CA-3' 
PS 9/8t  § 
PS 9/9t§  5"CTC  ATA ACC  TGC  TTA  AAG CTA-3' 
PS 9/4t  § 
PS  10/2t§  5"CCT  TAT CTG  CTT  AAC CTC TA-3' 
PS 21/lt 
PS  2211 t5  5"TCC  ATT TTG GlT  TGG TAT CA-3' 
PS  10/1* 
PS  22/2t§  5"GAC  ATT CCA AAT GAG TTG TAA-3' 
PS  12/2t 
PS  12/1*  5"GAG  TTC  ACT  TTC  CAC  TTT CC-3'  e1441  to 1460 
PS  17/lt  5"CCT  ATA CTC ATA ATC GAG CC-3'  -69  to -50 
-59  to -45 
+37 to +56 
5"TAG  ATT TAA TGT TTT TGG  TCC A-3'  -145  to -124 
+l0  to +29 
5"TAG  TTG  ATG  TCA  TAG TAT TCT T-3'  -139  to -118 
+l14 to +l34 
5"CAT  TAG TAA CCA AAC AAA AAT G-3'  -100  to +79 
+30 to +49 
5"GCT  TTC  TGT ATT TCT  TAC  TC-3'  -49  to -30 
+74 to +93 
5"AGA  AAT CAG  CAG  ATT TTC AG-3'  1100 to 1119 
-158  to -138 
5"GAT  CAT  TTC  AAG TTG  TCA  CTC-3'  +l13 to +l33 
PS  17/25  5"TAA  TCG  AGC  CAC  TGT-3' 
PS  13/lt 
PS  24St  5"GAT  CAT TGA GAA AGG GAA TGG-Y 
PS  14/lt§ 
5"TGG  GCA  CAC  AGT AGA TAC  TC-3'  +91 to +l10 
-135  to -115 
5"TGC  TGG  AGA TTG  TGC  CAA AC-3'  +l21  to +l40 
PS  EXIV-It§  5"AAA  AAC TCA AAA GTC  ACT  C-3' 
PS  EXIV-2t§ 
-75  to -57 
5"AAT  AAA TGT CGG TAC  TAG  CC-3'  +l31  to +l50 
PS  e14t  5"TAC  TGT AAT ATA TCG GAT-3'  e1814 to 1833 
PS  18/3*  5"ATA  GAA ACC  ATC  TCC  CAT  GA-3'  e1920 to 1939 
PS 19/lt§  5"GGA  TTA  GAA TTT GGT  TGG  AAA C-3'  -  106 to -85 
PS  16/25  5"AGA  GCT  CAC  TCA  TGT-3'  e2130 to 2144 
PS  1611  5  5"GTC  AAG GAA AAA AAT TCT  GTT  GTG  AT-3'  e2318 to 2343 
PS  2011 5  5"CAC  TAT TCT TAG ATA GCA AGA GAA GT-3'  e2368 to 2393 
PS  20125  5"GAT  ATC  TCA  TCC  TGA-3'  e2827 to 2841 
PS  20136  5"TTG  TGT  GGC  TTC  ACA-3'  e2720 to 2734 
PS-PlBtt  5"TGC  TGC  TCT  CAG GAA  AAT  A-3'  e2777 to 2795 
PS 25ASt5  5"GTG  GCA  ATC  TTA CCT  CCT  TA-3'  e3230 to 3149 
Locations of  primers are indicated by  the numbers of  the first and the last nucleotide; the -  or + placed in front gives locations upstream 
or downstream of  the respective exon. Numbers following  an  e are cDNA positions according to Hoskins et a134 characterizing nucleotides 
located  within exons. 
t Primer  for  amplification  of  genomic sequences.  * Primer for cDNA amplification. 
§ Primer for sequencing. 
chain  reaction  (PCR)"  products were  sequenced directly  by  the 
method of  Sanger?' Primers chosen for PCR amplification (of exons, 
including exon-intron boundaries; Table 2) were constructed from 
genomic sequences using differences between the PROS  1 and the 
PROS 2 genes."-"  They were positioned such that the 3'  end of at 
least one of the two primers was only complementary to the PROS 
I  gene. As no sequence differences between PROS 1 and  PROS  2 
were known for exon 3, we amplified this exon and large parts of 
boundering introns with primers presumed to be common to both 
genes. The PCR product (340 bp for PROS 1) was sequenced, and 
the differences found between the known PROS  1 gene sequence 
and the pseudogene sequence were used to design PROS l-specific 
primers PS-414  and PS45. 
All amplification products included at least 10 nucleotides of  5' 
and  3'  flanking intron sequences, except for only five nucleotides at 
the 5'  splice junction of exon 2 and only nine nucleotides at  the  3' 
splice junction of exon 7. Amplifications were performed in a DNA 
Thermal  Cycler  (Perkin-Elmer Cetus,  Norwalk,  CT)  using  Taq- 
DNA-polymerase (Roche Molecular Systems, Inc. Branchburg, NJ). 
The final concentrations of ingredients (for exons 2 to 15) were 0.2 
pmoVL each primer; 0.2 mmol/L each deoxynucleotide triphosphate 
(W);  10 mmol/L Tris-HC1 (pH 8.3 at 25°C); 50 mmol/L  KCl; 
MgC12 at 1.5 mmollL (for exons 2, 4, 5 + 6, 11, 13 + 14, 14). 2.0 
mmol/L (for exons 9 and 13), 2.5 mmol/L (for exons 7, 8,  10,  15), 
or 3.0 mmol/L  (for exons 3 and 12); 1.25 U Taq-DNA-polymerase; 
and approximately 500 ng of genomic DNA. 
Exon I was amplified in a buffer system containing dimethylsulf- 
oxide (DMSO) and  (NH4)2S04?3 After a  denaturation step of  3 
For personal use only. on November 2, 2014.  by guest    www.bloodjournal.org From POINT  MUTATIONS  IN  PROTEIN  S DEFICIENCY  3447 
Table 3.  Molecular  Defects Identified in Nine Patients  With Type I  Protein S Deficiency 
No. of [affected] 
cDNA  Family Memberdin  Mutant  Restriction 
Mutation  Position*  Generations  Cosegregation  RNA  Site  Comment 
mut-l: ACAAAG +  ACAG  2166,  2167  fam-1: 8I4l/3  Yes  Yes  2-bp deletion 
fam-4 2[11/2  Change of  reading frame 3 codons before 
stop codon, use of  new stop codon. 
The  last 3 amino acids (KNS)  are 
replaced by  23  amino acids 
(QFLRHLFSAYNTFSLCVIILMFQ) 
mut-2: GTACGT + GTACAT  lntronic  fam-2: 6[41/2  Yes  ND  Maell  Splice site mutation in splice donor of 
intron  10 
fam-3: 2[21/2 
mut-3: GTGGCC + GTGCCC  1992  fam-6: 4[31/2  Yes  Yes  Eae  I  Ala  575  + Pro 
mut-4 AATCTG 4 AATCAG  1897  fam-7:  2[21/2  -  Yes  Bpm  I  Leu  543+Gln 
mut-5: CTGTTA + CTGTCA  1801  fam-8:  6[51/3  Yes  Yes  Leu 51 1 + Ser 
mut-6 TCCTGA +  TCCCGA  1198  fam-9: 2[21/1  -  ND  Leu 310 +  Pro 
mut-7: ATACGA +  ATATGA  1497  fam-10:  5[31/2  Yes  No  Acc  I  Arg  410  4  STOP also present in the 
protein S  pseudogene (PROS 2) 
Abbreviations: -,  unknown; ND, not done. 
* cDNA  positions according to Hoskins et al." 
minutes at 93T, the 50-pL reaction mixtures were exposed to 35 
cycles of  1 minute denaturing at 93°C; 1 minute annealing at 45°C 
(exons 8, 12, and 14), 50°C (exons 2,3, 10, and 13), or 55°C (exons 
1, 4, 5 + 6, 7, 9, 11, and  15); and 2 minutes extension at 72°C. A 
final extension step at 72°C for  10 minutes assured completion of 
synthesis. With primers PS-24s and PS-EXIV-2 (exon 13 + 14). 10 
cycles with an annealing temperature of  60°C  were followed by 30 
cycles at 50°C. 
Because the pseudogene sequence at the  5'  end of intron 14 was 
not available, and intron 13 sequences were not appropriate to choose 
a PROS  1 gene-specific primer, 0.5-pL PCR products (containing 
parts of intron 12, exon 13, intron 13, exon 14, and parts of intron 
14) obtained with primers PS-24s and PS-EXIV-2 were submitted 
to  12 cycles of seminested amplification using primers PS-EXIV-1 
Purification of  PCR products was performed on low melting point 
agarose. Gel slices were melted (70Q  shock-frozen (-7O"C),  and 
centrifuged (12,OOOg) after thawing.29  Two to  five microliters of  the 
supernatant and  10 to  30 pmol primer were used  for sequencing 
with Sequenase v 2.0  (US  Biochemical, Cleveland, OH) and  [a- 
'5S]-deoxyadenosine triphosphate (dATP; Amersham, Amersham, 
UK). 
Index patients were sequenced in all exons. Any detected mutation 
was confirmed by analysis of the respective exon in  key  relatives. 
cDNA preparation.  Total RNA was isolated from 2 mL whole 
blood  using  a commercial kit  (Fastube RNA  Extraction System, 
ViennaLab,  Vienna,  Austria),  based  on  a  guanidinium  phenol 
and PS-EXIV-2. 
method.30  Half  the  RNA  obtained by  one isolation was used  for 
random-hexamer primed cDNA synthesis with M-MLV reverse tran- 
scriptase." 
Preparation of  PCR  products  for digestion  with  Acc l, Bpm l, 
BstXI,  and  Eae I.  Primers (Table 2) for amplification of  cDNA 
were constructed from exonic sequences of the PROS l gene. The 
primer pairs were located in adjacent exons, separated by  an  intron, 
to rule out amplification of genomic sequences. 
Amplifications of cDNA with primers PS-18/3 and  PS-P1B (1  pL 
cDNA, 40 cycles, annealing at 59°C) as well  as  of  genomic DNA 
with PS-19/1 and  PS-P1B  (500 ng  DNA,  35 cycles, annealing at 
55°C) were performed with 0.8 pmoVL each primer, 0.4 mmoVL 
each dm,  5 mmoVL Tris-HC1 (pH 8.0 at 37°C). 50 mmoVL NaCI, 
2.5  mmoVL  MgCI2, 1 mmoVL 2-mercaptoethanol, and 1.25 U Taq- 
DNA-polymerase. 
The buffer used for amplification of cDNA with primers 10/1 and 
1511 (1 pL cDNA, seven cycles annealing at 62°C followed by  33 
cycles at 50°C; 0.4 pmom each primer, 0.4 mmoVL  each dNTP, 
2.5 U Taq-DNA-polymerase) as well as of genomic DNA  with  prim- 
ers PS-el4 and PS-EXIV-2 and primers PS-13/1 and PS-17/1 (500 
ng DNA, 35 cycles, annealing at 55°C; 0.2 pmoVL each primer, 0.2 
mmom each dNTP,  1.25 U Taq-DNA-polymerase) contained 16.5 
mmol/L Tris-acetate (pH  7.9  at  37°C).  33  mmoVL  K-acetate, 5 
mmoVL Mg-acetate, and  0.5  mmoVL  dithiotreitol. The respective 
enzyme (ACC  I,  10 U;  BstXI, 5 U;  Eae  I,  10 U  [all Boehringer 
Mannheim, Mannheim, Germany]; and Bpm I, 4 U  [New England 
BioLabs, Beverly, MA]) was added to  10 pL of  unpurified  PCR 
..  ..  :: 
... 
93  .. .  10  M  11  H  12  H  13  H  14  H  15 
:. 
+  ++  +  I 
82  7  548  1 
Fig 1.  Diagram  of the second  half  of the PROS 1 gene.  Exons are symbolized by rectangles in scale, introns by connecting  lines.  The upper 
part of the graph  shows the position of the primers used  for  amplification of cDNA.  Bold  numbers  in  the lower part of the figure  give  the 
location of the respective mutation. 
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I  TI. 
fam- I  fam-2 
fam-3  fam-4 
fam-7 
I1  = 
fam-6 
I2 
fam-l0 
Fig 2.  DNA-typed individuals  in their geniologic relation to each 
other. Black  symbols indicate individuals with heterozygous  PS-de- 
ficiency.  index  patients are indicated by an arrow. An  asterisk  (*l 
marks individuals with thromboembolic events. 
amplification  product,  and  the  digests  were  incubated  at 37°C (Acc 
I, Eae  I, Bpm I) and  45°C  (BsrXI) for 3 to  15  hours.  The cleavage 
products  were  analyzed  on  precast 6% polyacrylamide  gels  (Novex, 
San  Diego,  CA),  followed  by  staining  with  ethidium  bromide. 
Heteroduplex  analysis of mut-I.  Genomic  DNA  was  amplified 
with  primers  PS-19/1  and  PS-P1B.  PCR  products  were  separated  at 
constant  voltage  (100  V) on  precast  6% polyacrylamide  gels. 
RESULTS 
For  all  10 index  patients,  heterozygous hereditary  protein 
S deficiency  type I was verified on the  basis  of  their free 
and total  protein  S values (Table l),  as well as their  family 
histories  of  protein  S deficiency. Except patient 243,  who 
experienced  only  one  thrombotic  event,  all  index  patients 
had recurrent  thrombosis. 
Results of DNA analysis.  In  nine  index  patients,  seven 
different  mutations  (mut-l  through  mut-7;  Table  3,  Fig  l) 
were identified by  direct  sequence analysis  of  all  exons  and 
splice  regions of the  PROS 1 gene. For five mutations (mut- 
1,  -2,  -3,  -5,  -7),  cosegregation  with  the  disease  could  be 
demonstrated.  For  mut-4  family 7 and  mut-6  family 9, this 
was not  possible,  because pedigrees  were  incomplete  (Fig 
2).  All  seven  mutations  were  absent in  44 to  62  normal 
individuals. 
In addition to the  mutations,  the  exonic  G/A  dimorphism 
in  codon 62632,33  and  two  unpublished  dimorphisms,  one 
exonic  and  one  intronic,  were  identified  in  some patients. 
These  two  dimorphisms were also  found in 30 healthy  con- 
trol individuals with an  allelic  frequency  of  more  than  10% 
(data not shown).  No  other  genetic alterations  were  seen  in 
the  tested  sequences. 
Among  the  seven  identified  mutations, three have  a  major 
impact  on  the  expected  gene  product:  a  2-bp  deletion.  a 
splice  site  mutation,  and  a  nonsense  mutation. 
The 2-bp  deletion  (mut-l) at cDNA positions  2166  and 
2167 (cDNA numbering  according  to  Hoskins  et  al”)  leads 
to a changed  reading  frame.  The  mutation was found  in two 
unrelated  index  patients  (1-1V4 and  4-VI).  Both of them had 
experienced recurrent  thrombosis.  For patient  1 -W4, three 
protein  S-deficient  relatives  (two of  them  symptomatic) as 
well  as  four relatives  with  normal  protein  S  values  were 
tested for the  mutation  by heteroduplex  analysis.  All protein 
S-deficient  family members were found  to  carry  the  deletion, 
while it was absent in all  unaffected  relatives  (Table  1) and 
in 44 normal  controls. 
The mutation  in  the donor  splice  site of intron  10 (mut- 
2)  presumably  affects  splicing.”  It  was  observed  in  two 
unrelated  index  patients (2-1/3 and 341)  who both  had expe- 
rienced  thrombosis.  By direct sequencing of  PCR  products 
(PS-21/1 and PS-22/1),  this  mutation  could  be  demonstrated 
in  all  protein  S-deficient  relatives  of  both  index  patients, but 
was not  present  in  the unaffected  relatives  or in a group of 
45 normal  control  individuals. 
The  nonsense  mutation  in  family IO  (mut-7)  converts  argi- 
nine-410  into a stop  codon. Direct sequencing demonstrated 
the presence of this  mutation  in  all  three protein  S-deficient 
members  of  this  family,  of  whom  two  had  experienced 
thrombosis.  In  two  relatives  with  normal  protein  S values, 
as well as in 44 unrelated normals,  the mutation  was  absent. 
Interestingly,  the  same  mutation  is  found  in  the  protein  S 
pseudogene  (PROS 2). 
Three missense  mutations  were  identified  in  exon  14 of 
index  patients  6-V1, 7-1/1, and  8-IIVI: mut-3  (Ala  575  to 
Pro), mut-4  (Leu  543  to  Gln),  and  mut-5  (Leu  51  1 to  Ser), 
respectively.  All  three missense  mutations were  present  in 
the  protein  S-deficient  family  members but  absent  in  rela- 
tives  with  normal  protein S levels,  and in 46,  52,  and  52 
normal  individuals.  Another  missense mutation  (mut-6)  was 
identified  in exon 10. This mutation changes Leu 310  to  Pro, 
and was identified in two protein  S-deficient  brothers. It was 
absent  in  62 normal  individuals. 
Results of  RNA analysis.  RNA isolated from peripheral 
blood  of  six  patients  was  available  for  RNA  studies.  Four 
individuals  (patients  LW4,  4-Y1,  741, and 8-IIV2)  were 
heterozygous  for  the  codon  626  G/A  dimorphism,  which 
affects  a  Bst X1 restriction  site.  In  all four patients, cDNA 
amplification  (PS-18/3  and  PS-PlB)  and  digestion  with  Bst 
XI proved  the  presence  of mutant  and  wild type  RNA  (Fig 
3A). Haplotypes of affected  alleles  (obtained  from pedigree 
analysis; data  not  shown)  were G in families I and 4 and A 
in  family  8. Visual  inspection  of the Polaroid  photographs 
indicated higher  concentrations of normal  transcripts  in  pa- 
tients  l -11/4, 4-1/1, and 8-111/2. The  haplotype  of the mut-4 
allele  (family  7)  could not be determined. In families 6 and 
10 no individual was  heterozygous for  the  codon  626  dimor- 
phism.  Because  mut-3 causes the loss of an Eue I  site and 
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Fig 3.  (A) Ratio of normal and mutant  protein  S transcripts in four  deficient  patients.  BsrXl digests of cDNA amplification  products (PS-18/3 
and PS-PlB), containing  the  codon 626 GIA-dimorphism.  Normal  and  mutant  alleles are present in  patient 1-11/4 (lane l),  patient 441 (lane 2). 
patient 741  (lane 3). and  patient 8-11112  (lane 4). The smaller band in patients 1-11/4 and 441  and  the larger band in patient 8-111/2  represent the 
normal allele (haplotypes  constructed  from  family studies). In all  three  patients  the  normal allele prevailed. For 741  the  haplotype  is unknown. 
The left and  the  right lanes show pBR322-Msp I marker bands at 622 bp and 527  bp. IBI RNA analysis in  patient 6-1/1. Digestion of cDNA PCR 
products, obtained with primers PS-18/3 and PS-PlB, by Eae I gives a band  at 876 bp in case of the  wild-type sequence and a band at 803 bp  in 
the presence of mut-3.  Middle lane,  patient 6-111 with bands at 876 and 803 bp. Right lane,  normal  control. Left lane, pBR322-Msp  I  marker. (C) 
RNA analysis in  patient  10-1/2. Acc I digestion  of cDNA PCR  products generated with primers PS-10/1 and PS-15AS.  Bands at 412,  322,  and 73 bp 
represent the  normal  transcript.  Mut-7  would  result in a loss of an Acc I cleavage site and the generation of bands at 485  and 322  bp.  Left lane, 
patient 10-1/2. Right lane, pBR322-Msp I marker. All  digests  were analyzed on 6% precast polyacrylamide gels. 
mut-7,  the  loss of an Acc  I site,  restriction  enzyme  cleavage  mented family history of protein S deficiency  and  thrombo- 
could be used  for  the  detection of  mutant  transcripts.  After  embolism. Seven different, putatively  causal  mutations  were 
digestion  with &e  1.  uncleaved (876 bp) mutant and  cleaved  identified in 9 of 10 unrelated  patients with hereditary protein 
(803 bp + 73 bp) wild type Sequences  could be  Seen  in equal  S deficiency. Major evidence for  pathogenicity of these mu- 
amounts in the  cDNA PCR product of patient 6-1/1 (Fig 3R).  tations  was their at-,sence  in a group of normal  controls  (44 
Cleavage or the  respective cDNA PCR product  (ps-I0/1  and  to 62 individuals).  ,411  mutations  were  also the only genetic 
PS-15-AS) from  patient 10-1/2  with Act*  l  resu1ted in the  abnormalities found in the investigated sequences  of the pro- 
generation  of  three  bands  with 412, 322, and 73 bp, repre- 
senting wild  type.  No mutant  transcript  (expected bands  at 
485, 322 bp) was present (Fig  3C). 
tein S-deficient  individuals.  Pedigree analysis was  performed 
to distinguish  these  putatively  causal  mutations  from  DNA 
alterations not linked to protein S deficiency. For five muta- 
tions  (mut-l.  -2.  -3. -5. and  -7).  the  transmission  within 
We established a useful protocol  for  the  detection  of gene  sufficiently  large  families  could  be studied,  and  all five muta- 
DISCUSSION 
alterations in the PROS  I  gene in patients with a well-docu-  tions  cosegregated  with the  disease. 
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The causality  of  the  2-bp  deletion  (mut-l)  and  the splice 
site  mutation (mut-2)  for  protein S deficiency  is  supported  by 
the occurrence of each mutation in two different,  reportedly 
unrelated  protein  S-deficient  families. Mut-2  was  also  identi- 
fied in two of eight genetically  investigated  Dutch  families 
with  protein  S deficiency.”  Whether this high  frequency  of 
mut-2 is due  to  the  presence  of a mutational hot  spot  remains 
to  be  determined. 
The  deletion  of two  adenines  in  codon  633  leads to  the 
use  of  a  new  reading  frame.  The  normal  stop  codon  is 
skipped  and  a  new  stop  codon  62  bases  downstream  comes 
in  frame.  The  new  sequence  codes  for  23  amino  acids 
(QFLRHLFSAYNTFSLCVIILMFQ), including  one  cys- 
teine,  instead of only three  amino  acids  (KNS) in individuals 
with  normal  protein  S. As  we  could  demonstrate  transcrip- 
tion  of  mutant  RNA, it is  feasible  that  an  aberrant  protein 
is translated  from this mutant  RNA.  The  secretion  of  this 
protein  would  presumably  be impaired  due  to  interference 
with  proper  folding of  one unpaired  cysteine  contained  in 
the extra  amino  acid  ~equence.’~~’~ 
Mutation  mut-7  introduces a stop  codon at the beginning 
of exon 12. Aberrant RNA  is absent from  ectopic transcripts 
in  blood  cells,  and a  truncated  gene product  in protein  S 
synthesizing cells is  unlikely. 
Mutations  mut-3  and  mut-6  lead  to  the  replacement  of 
alanine-575  and  leucine-3  10,  respectively, by proline,  which 
is known  to interrupt the formation of any  regular  repeating 
structure. This  could destabilize the conformation of protein 
S, making  it  vulnerable  against degradation  or retaining  it 
from  secretion."^" In a secondary  structure  model  of  protein 
S reported  by  Schmidel  et  all8  and  calculated  according  to 
Chou  and  Fasman,”  proline-575 would lie in the region of 
a  conversion  of  an  a-helical  into  an  irregular  structure. Using 
the  same model, proline-310 would  disrupt  a region  of  pre- 
dicted p sheet structure and  would,  therefore,  significantly 
impair  the  secondary structure. 
Common  to  mut-4  and  mut-5  is  the  change  of leucine,  a 
hydrophobic amino acid, into a  polar  amino acid: glutamine 
and serine,  respectively.  Leucine-543 (mut-4)  is  conserved 
in human, bovine,38 mouse,’’  and rabbit4’ protein  S amino 
acid sequences.  At position S1 1 (mut-S),  all three  nonhuman 
protein  S sequences carry hydrophobic valine.  Apparently, 
there is  a  demand  for  branched,  aliphatic  amino  acids  at 
position 543  and  5 1  1,  as evidenced by the  high conservation 
during  evolution. 
We  could detect  transcripts  of the mutant  allele  in four of 
five different  mutations  when  we analyzed cDNA generated 
from total RNA.  No  mutant  transcript was  found in the case 
of the  stop  codon.  In the  presence  of the  2-bp  deletion and 
the Leu-51 1  to  Ser  mutation,  the concentration  of  mutant 
transcripts was  lower than of wild  type.  Our results  indicate 
that  RNA  analysis  is  not  suitable  for  the  detection  of  all 
mutations in the  PROS  1 gene,  such as Arg-410  to  stop,  and 
only  DNA  analysis  is  adequate.6 
Interestingly,  a  high  frequency  of  missense  mutations 
(four of seven)  was  observed.  Similar results  have  already 
been  reported  for  gene  alterations  in  hereditary  protein  C 
deficiency, in which more than half of  all mutations  are  also 
missense  mutations.4’ 
The identification of  mutations  in  the PROS  I  gene  not 
only contributes  to the  understanding  of pathogenic  muta- 
tions, but helps to clarify  diagnostic  uncertainties.  It is well 
known  that  an  overlap of  free  and  total  protein  S  values 
exists in deficient patients  and  normal  controls. We observed 
slightly  reduced  free  and  normal  total  protein  S  values  in 
individual  4-1UI  (daughter of  a  protein  S-deficient  father), 
and  her protein S deficiency  status was unclear. Gene analy- 
sis  could  redress  uncertainties  by demonstrating  absence of 
the  PROS  1 gene mutation  in  this  individual.  Thus,  our 
study also shows the  value  of gene  analysis  for  diagnostic 
applications. 
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